公开(公告)号：US10695445B2

公开(公告)日：2020-06-30

申请号：US16143682

申请日：2018-09-27

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Raghavan Rajagopalan ,  Dennis A. Moore ,  Scott T. Depierro

IPC: A61B5/00 ,  A61K49/00 ,  A61B5/20 ,  A61B17/00 ,  A61B17/42

Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

公开(公告)号：US20200155709A1

公开(公告)日：2020-05-21

申请号：US16694994

申请日：2019-11-25

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Thomas E. Rogers

IPC: A61K49/00 ,  A61B5/00 ,  C07K5/078 ,  C07D241/20

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

公开(公告)号：US20200155708A1

公开(公告)日：2020-05-21

申请号：US16694982

申请日：2019-11-25

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Thomas E. Rogers

IPC: A61K49/00 ,  A61B5/00 ,  C07K5/078 ,  C07D241/20

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

公开(公告)号：US20190194172A1

公开(公告)日：2019-06-27

申请号：US16289509

申请日：2019-02-28

Applicant: MediBeacon Inc.

Inventor： William L. Neumann ,  Raghavan Rajagopalan ,  Richard B. Dorshow

IPC: C07D405/04 ,  C07D241/26 ,  C07D241/20 ,  A61K49/00 ,  C07D401/04 ,  C07D473/34 ,  C07D473/18 ,  C07D417/04 ,  C07D413/04 ,  C07D409/14 ,  C07D409/10 ,  C07D409/06 ,  C07D409/04 ,  C07D403/14 ,  C07D403/12 ,  C07D403/04 ,  C07D401/14 ,  C07D241/28 ,  C07D241/24 ,  C07D241/12

CPC classification number: C07D405/04 ,  A61K49/0021 ,  C07D241/12 ,  C07D241/20 ,  C07D241/24 ,  C07D241/26 ,  C07D241/28 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D409/04 ,  C07D409/06 ,  C07D409/10 ,  C07D409/14 ,  C07D413/04 ,  C07D417/04 ,  C07D473/18 ,  C07D473/34

Abstract: The present invention relates to pyrazine derivatives capable of absorbing and emanating spectral energy in the visible and/or near infrared spectrum. Pyrazine derivatives of the invention may be administered to a patient in the form of a pharmaceutically acceptable composition and utilized in medical (e.g., diagnostic imaging) procedures.

公开(公告)号：US20190192694A1

公开(公告)日：2019-06-27

申请号：US16289487

申请日：2019-02-28

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Thomas E. Rogers

IPC: A61K49/00 ,  C07K5/078 ,  A61B5/00 ,  C07D241/20

CPC classification number: A61K49/0021 ,  A61B1/042 ,  A61B5/0071 ,  A61B5/0082 ,  A61B5/0261 ,  C07D241/20 ,  C07K5/06139

Abstract: The present disclosure relates to compositions and methods for assessing blood vessels and organs of the body, more specifically to methods for assessing the vasculature of the eye.

公开(公告)号：US20190142976A1

公开(公告)日：2019-05-16

申请号：US16200353

申请日：2018-11-26

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Steven J. Hanley ,  Phillip I. Tarr

IPC: A61K49/00

Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.

公开(公告)号：US20190125902A1

公开(公告)日：2019-05-02

申请号：US16171695

申请日：2018-10-26

Applicant: MediBeacon Inc.

Inventor： Raghavan Rajagopalan ,  Richard B. Dorshow ,  William L. Neumann ,  Thomas E. Rogers

IPC: A61K49/00 ,  A61B5/20 ,  A61B5/00 ,  A61M5/00

Abstract: The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.

公开(公告)号：US20190022256A1

公开(公告)日：2019-01-24

申请号：US16143682

申请日：2018-09-27

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Raghavan Rajagopalan ,  Dennis A. Moore ,  Scott T. Depierro

IPC: A61K49/00 ,  A61B5/00 ,  A61B5/20 ,  A61B17/00 ,  A61B17/42

Abstract: In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.

公开(公告)号：US20180110881A1

公开(公告)日：2018-04-26

申请号：US15572706

申请日：2016-05-12

Applicant: MediBeacon Inc.

Inventor： Richard B. Dorshow ,  Thomas E. Rogers

IPC: A61K49/00 ,  C07D241/20 ,  A61B5/00

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

公开(公告)号：US20170298030A9

公开(公告)日：2017-10-19

申请号：US15178799

申请日：2016-06-10

Applicant: MediBeacon Inc.

Inventor： Raghavan Rajagopalan ,  Richard B. Dorshow ,  William L. Neumann ,  Dennis A. Moore

IPC: C07D241/28 ,  A61K49/00 ,  C07D241/20 ,  C07D241/26 ,  A61K31/4965

CPC classification number: C07D241/28 ,  A61K31/4965 ,  A61K49/0004 ,  A61K49/0021 ,  A61K49/0052 ,  C07D241/20 ,  C07D241/26

Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 of Formulas I and II may be characterized as electron withdrawing groups, while Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.